【摘要】：冠心病發(fā)病率逐年升高,PCI術(shù)后應(yīng)用替羅非班可以減少患者缺血事件,降低患者死亡率,然而出血、血小板減少等并發(fā)癥是不可忽視的,關(guān)于如何合理應(yīng)用替羅非班使其發(fā)揮最大作用又減少并發(fā)癥,我們進(jìn)行了研究。
[Abstract]:The incidence of coronary heart disease is increasing year by year. The use of tirofiban after PCI can reduce the ischemic events and reduce the mortality of patients. However, complications such as hemorrhage and thrombocytopenia can not be ignored. We have studied how to use tirofiban properly to maximize its effectiveness and reduce complications.
【作者單位】： 濟(jì)南大學(xué);山東省醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與生命科學(xué)學(xué)院;山東省醫(yī)學(xué)科學(xué)院附屬濟(jì)寧市第一人民醫(yī)院心內(nèi)科;濟(jì)寧市第一人民醫(yī)院高新區(qū)分院心內(nèi)科;
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 申紅遠(yuǎn);梁偉;湯U，

本文編號(hào)：2125869